The role of interleukin inhibitors in the treatment of hidradenitis suppurativa; a systematic review of clinical trials
- 21 April 2025
- journal article
- review article
- Published by Elsevier in Autoimmunity Reviews
- Vol. 24 (7) , 103818
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Interleukin-17 Inhibitors in the Treatment of Hidradenitis SuppurativaBioDrugs, 2024
- Efficacy and safety of radiofrequency in the treatment of hidradenitis suppurativa; a systematic reviewLasers in Medical Science, 2024
- A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatmentInternational Immunopharmacology, 2023
- Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled TrialDermatology and Therapy, 2023
- Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis SuppurativaJAMA Dermatology, 2021
- Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive ReviewAmerican Journal of Clinical Dermatology, 2020
- Safety and Efficacy of Anakinra in Severe Hidradenitis SuppurativaJAMA Dermatology, 2016
- Epidemiology of Hidradenitis Suppurativa: Prevalence, Pathogenesis, and Factors Associated with the Development of HSCurrent Dermatology Reports, 2013
- Th17 CellsThe American Journal of Pathology, 2012
- Hidradenitis SuppurativaArchives of Dermatology, 2012